Q2 2026 13F · SEC CIK 1542339
Essex Woodlands Management, Inc.
Hedge fundFiled 2026-08-04 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $254.2M
- Reported positions
- 5
- Top holdings a year, 3 yrs
- -2.3%
- Assets under management
- $2.1B
Essex Woodlands Management, Inc. is a hedge fund that reported 5 positions worth $254.2M in its Q2 2026 13F, filed 2026-08-04. Its largest holdings were Bioventus Inc (BVS, 48.4%), Mimedx Group Inc (MDXG, 42.7%), Eyepoint Pharmaceuticals Inc (EYPT, 6.1%). A portfolio copying its top holdings returned -2.3% a year over the last 3 years, against 20.4% for the S&P 500.
Essex Woodlands Management, Inc. holdings all 5 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| BVSBioventus Inc | 48.4% | +0.0% | $122.9M |
| MDXGMimedx Group Inc | 42.7% | +0.0% | $108.6M |
| EYPTEyepoint Pharmaceuticals Inc | 6.1% | +0.0% | $15.5M |
| TELATela Bio Inc | 2.3% | +0.0% | $5.8M |
| MNOVMedicinova Inc | 0.6% | +0.0% | $1.5M |
What Essex Woodlands Management, Inc. bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -8.0% /yr
- S&P 500 +20.1%
- 3 years
- -2.3% /yr
- S&P 500 +20.4%
- 5 years
- -19.1% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $254.2M | 5 |
| Q1 2026 | $250.5M | 5 |
| Q4 2025 | $318.3M | 6 |
| Q3 2025 | $307.1M | 6 |
| Q2 2025 | $279.1M | 6 |
| Q1 2025 | $346.7M | 6 |
| Q4 2024 | $433.2M | 7 |
| Q3 2024 | $350.4M | 7 |
| Q2 2024 | $306.7M | 7 |
| Q1 2024 | $344.8M | 7 |
| Q4 2023 | $404.1M | 7 |
| Q3 2023 | $113.4M | 6 |
Questions about Essex Woodlands Management, Inc.'s portfolio
What stocks does Essex Woodlands Management, Inc. own?
Essex Woodlands Management, Inc.'s latest 13F, for Q2 2026 and filed Aug 4, 2026, lists 5 positions worth $254.2M. The largest are Bioventus Inc (BVS) at 48.4%, Mimedx Group Inc (MDXG) at 42.7%, Eyepoint Pharmaceuticals Inc (EYPT) at 6.1%, Tela Bio Inc (TELA) at 2.3% and Medicinova Inc (MNOV) at 0.6%.
What did Essex Woodlands Management, Inc. buy last quarter?
Essex Woodlands Management, Inc. opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did Essex Woodlands Management, Inc. sell last quarter?
Essex Woodlands Management, Inc. sold out of nothing and cut no large position by more than 5% in Q2 2026.
How has Essex Woodlands Management, Inc.'s portfolio performed?
A portfolio copying Essex Woodlands Management, Inc.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned -2.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: -8.0% against +20.1%. Over 5 years: -19.1% a year against +11.6%.
When is Essex Woodlands Management, Inc.'s next 13F filing due?
13F filings are due 45 days after each quarter ends. Essex Woodlands Management, Inc.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Essex Woodlands Management, Inc. manage?
Essex Woodlands Management, Inc. reported $2.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $254.2M.